RxCelerate, one of the leading out-sourced drug discovery and development platforms in the United Kingdom, announced today it has hired Laura Hamilton as Executive Vice President, US Operations and opened an office in Cambridge, MA, just outside Boston. “We are bringing RxCelerate’s unique model for out-sourced drug discovery and development to the heart of the largest and most vibrant life sciences cluster on the planet” said Jill Reckless, CEO of RxCelerate.
RxCelerate offers a fully integrated discovery and development service to the pharma and biotech industry, ranging from medicinal chemistry, antibody discovery, preclinical safety and efficacy through to clinical proof of concept. “Contract Research Organisations often provide an excellent way of increasing capacity, acting as extra pairs of hands to perform experiments you design with them” said David Grainger, Executive Chairman at RxCelerate, “but RxCelerate is different. We are architects of drug discovery and development, rather than builders. Our clients need provide nothing more than the target they are interested in, and RxCelerate will deliver a pharma-grade product candidate and progress it into the clinic.”
Founded in 2012 in Cambridge, UK, the RxCelerate team has quickly grown to more than 40 experienced scientists. Clients range from entirely virtual start-ups, using RxCelerate as their infrastructure, through to three of the top fifteen global pharmaceutical companies. “With our home in Europe’s largest bioscience cluster, establishing a base in the epicenter of American biotech seemed to be the logical next step. We already have a number of US clients, but this new move brings us right to their doorstep” said Dr Reckless.
“As the Massachusetts life sciences cluster keeps growing, led by the cutting-edge research at our world-class hospitals and universities, the demand for out-sourced drug discovery and development platforms continues to increase,” said Robert K. Coughlin, President & CEO of Massachusetts Biotechnology Council (MassBio). “I’m confident that RxCelerate will help fill an important role in our state’s biopharma ecosystem.”